Results 71 to 80 of about 11,659 (170)

Sclerostin – új terápiás célpont osteoporosisban

, 2017
A sclerostinnak, az osteocyták által termelt glikoproteinnek csontanyagcserében betöltött szerepe kapcsán merült fel terápiás célpontként való hasznosíthatósága.
Pratz Anita, Nagy, György
core  

The regulation of the sclerostin gene and the catabolic effects of sclerostin protein on bone. [PDF]

, 2014
Age and disease-related bone loss is a major health issue. Bone tissue is constantly remodelled throughout life in order to maintain a healthy skeleton and bone loss is caused by an imbalance in the remodelling process.
Wijenayaka, Amugoda Kankanange Asiri R.
core  

Sclerostin levels in patients with acromegaly

Endokrynologia Polska
Acromegaly is a rare, endocrine condition characterized by autonomous excessive secretion of growth hormone, causing numerous complications, including impairment of bone microarchitecture. The increased bone turnover observed in acromegaly can lead to bone fragility and elevated risk of vertebral fractures despite normal bone mineral density measured ...
Arnika, Wydra, Jakub, Wydra, Jagoda, Rogowska, Wojciech, Zgliczyński, Izabella, Czajka-Oraniec   +4 more
openaire   +2 more sources

Association of serum sclerostin with bone sclerostin in chronic kidney disease is lost in glucocorticoid treated patients

, 2019
: The osteocytic protein sclerostin inhibits bone turnover. Serum sclerostin rises early in chronic kidney disease (CKD), but if this reflects osteocyte sclerostin production is unclear, since sclerostin is also expressed in extra-skeletal tissue ...
Lindholm, Bengt, Stenvinkel, Peter, d' Haese, Patrick C., Behets, Geert, Haarhaus, Mathias, Boltenst\ue5l, Hendrik, Qureshi, Abdul Rashid   +6 more
core  

Sclerostin in mineralized matrices and van Buchem disease

, 2009
Sclerostin is an inhibitor of bone formation expressed by osteocytes. We hypothesized that sclerostin is expressed by cells of the same origin and also embedded within mineralized matrices.
Oostenbroek, H.J., Hamersma, H., Gortzak, R. A., Van Hul, Wim, van Bezooijen, R.L., Hamdy, N.A.T., van Bezooijen, R. L., Van Hul, W., Bronckers, A. L., Papapoulos, S.E., Balemans, Wendy, Gortzak, R.A., Bronckers, A.L., Löwik, C.W.G.M., Lowik, C. W. G. M., Hogendoorn, P.C.W., Balemans, W., Hogendoorn, P. C. W., Hamdy, N. A. T., Dikkers, F.G., Papapoulos, S. E., van der Wee-Pals, L., Oostenbroek, H. J., Dikkers, F. G.   +23 more
core   +1 more source

Role and mechanism of action of Sclerostin in bone

, 2017
After discovering that lack of Sost/sclerostin expression is the cause of the high bone mass human syndromes Van Buchem disease and sclerosteosis, extensive animal experimentation and clinical studies demonstrated that sclerostin plays a critical role in
Sato, Amy Y., Bellido, Teresita, Delgado-Calle, Jesus   +2 more
core   +1 more source

B4GALNT3 regulates glycosylation of sclerostin and bone mass

, 2023
Summary Background: Global sclerostin inhibition reduces fracture risk efficiently but has been associated with cardiovascular side effects. The strongest genetic signal for circulating sclerostin is in the B4GALNT3 gene region, but the causal gene is ...
Lerner, U. H. (Ulf H.), Movérare-Skrtic, S. (Sofia), Horkeby, K. (Karin), Luong, T. T. (Trang Thi Doan), Koskela, A. (Antti), Wu, J. (Jianyao), Nethander, M. (Maria), Nilsson, K. H. (Karin H.), Li, L. (Lei), Voelkl, J. (Jakob), Henning, P. (Petra), Alesutan, I. (Ioana), Tuukkanen, J. (Juha), Ohlsson, C. (Claes), Lagerquist, M. K. (Marie K.), Tobias, J. H. (Jon H.)   +15 more
core  

Sclerostin serum levels in patients with systemic autoimmune diseases.

, 2016
Systemic autoimmune diseases (SADs) are associated with lower bone mass and an increased risk of fractures. Sclerostin has a pivotal role in bone metabolism.
Fernández-Roldán, Concepción, López-Mejías, Raquel, Robles, Concepción López, Mijares, Verónica, Callejas-Rubio, José Luis, González-Gay, Miguel Á, Ruiz, Manuela Expósito, Ortego Centeno, Norberto, Genre, Fernanda, Ubilla, Begoña, Fernández, Raquel Ríos, Cano, Daniel Sánchez   +11 more
core   +1 more source

Sclerostin expression in bone tumours and tumour-like lesions

, 2016
Aims To assess the immunophenotypic and mRNA expression of sclerostin in human skeletal tissues and in a wide range of benign and malignant bone tumours and tumour-like lesions.
Munemoto, M, Tanaka, Y, Inagaki, Yusuke, Hassan, AB, Munemoto, Mitsuru, Hassan, Andrew B., Hookway, ES, Athanasou, NA, Kashima, Takeshi G., Inagaki, Y, Athanasou, Nicholas A., Tanaka, Yasuhito, Oppermann, UCT, Hookway, Edward S., Oppermann, Udo C.T., Kashima, TG   +15 more
core   +1 more source

Sclerostin and the Unloading of Bone [PDF]

Journal of Bone and Mineral Research, 2009
openaire   +2 more sources